Ribosome Inactivating Proteins, Type 1
"Ribosome Inactivating Proteins, Type 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Ribosome inactivating proteins consisting of only the toxic A subunit, which is a polypeptide of around 30 kDa.
| Descriptor ID |
D054789
|
| MeSH Number(s) |
D08.811.277.450.430.700.500 D12.776.765.710.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribosome Inactivating Proteins, Type 1".
Below are MeSH descriptors whose meaning is more specific than "Ribosome Inactivating Proteins, Type 1".
This graph shows the total number of publications written about "Ribosome Inactivating Proteins, Type 1" by people in this website by year, and whether "Ribosome Inactivating Proteins, Type 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribosome Inactivating Proteins, Type 1" by people in Profiles.
-
Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget. 2015 Oct 06; 6(30):30194-211.
-
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb; 98(2):217-21.
-
The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma. Biochem Pharmacol. 2012 Aug 15; 84(4):451-8.
-
Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther. 2012 Jan; 11(1):143-53.
-
Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. BMC Cancer. 2011 Aug 17; 11:358.
-
Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma. Mol Imaging Biol. 2011 Aug; 13(4):721-9.
-
Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res. 2011 Apr 15; 17(8):2328-38.
-
The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia. 2010 May; 12(5):366-75.
-
The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood. 2007 Mar 15; 109(6):2557-64.
-
Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res. 2006 Nov 15; 66(22):10919-28.